Vir Biotechnology, Inc., a clinical-stage immunology company focused on treating and preventing serious infectious diseases, announced that the first patient was dosed in late December 2020 in a Phase...

On Tuesday, Vir Biotechnology & GSK announced the COMET-ICE study evaluating VIR-7831, a fully human anti-SARS-CoV-2 monoclonal antibody, will continue into Phase 3 based on an Independent Data Monitoring...